New Swiss drug R&D information web site

26 November 2007

The three Swiss pharmaceutical associations, Interpharma, the VIPS and the SGCI/SSIC Chemie Pharma Schweiz, have combined on a public awareness program concerning drug R&D. As part of the campaign, a new web site has been launched (www.pharma-recherche.ch) and two television advertisements broadcast on Swiss television.

The web site is designed to provide data on drug R&D in a user-friendly format to the general public. The Interpharma said that "the major themes at the moment are age-related blindness, cancer, multiple sclerosis and cardiovascular diseases." The group added: "from December, interesting interviews with leading lights in the Swiss research field will be published at regular intervals in a streaming video format." An on-line bulletin will also be made available concerning new developments in Switzerland's pharmaceutical sector.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK







Today's issue

Company Spotlight